HOUSTON, TEXAS – 12-14-2018 (PRDistribution.com) — The Neurology Center, a medical group practice of top doctors devoted to excellence in care, located in Houston, Texas, working in conjunction with two leading neurology and anti-aging Houston based specialists announced completing infusions for thirty-four of the forty Parkinson’s disease and Multiple Sclerosis patients in their randomized, controlled study of intravenously administered young Fresh Frozen Plasma (yFFP) provided by NuPlasma® and the initial test results of four of the MS patients. Only one month into the double-blind, placebo-controlled study, designed to evaluate the efficacy of 25 ml/kg intravenously delivered “young” plasma (volunteer donated blood plasma from adults between the ages of 18-25 years old), administered in two doses over three days, positive changes in blood biomarkers and life quality among MS patients, and a motor-examed PD patient, have been documented. The trending of observed biomarkers points toward a gradual improvement in the debilitating condition after only the first month of yFFP infusions, verifiable by the placebo test.
“The completion of infusions into all forty patients will mark a significant milestone. One-month results for all forty patients are expected to be released in early February 2019, three-month results in April and the six-month, final study assessments are to be concluded by July. It is our objective to determine from this study if subjective insights from the previous infusions of non-study patients and encouraging advances identified today from those patients receiving yFFP vs the saline placebo, confirm the practical use of yFFP to treat Parkinson’s disease and Multiple Sclerosis,” said Dian Ginsberg, M.D. (ABAARM, FAARFM), the 2018 A4M Congress’ Advances and Applications in Regenerative Medicine session moderator and “Young Plasma Transfusions for MS, Parkinson’s, and Overall Longevity” presenter. “We are cautiously optimistic that the patients that received the NuPlasma infusions will continue to improve in the coming months, a progression which we will strictly scrutinize and document.” Dr. Ginsberg, also speaking on behalf of study participants Igor Cherches, M.D. from The Neurology Center and neurologist Eddie Patton, M.D., said, “We are pleased to be involved in a sound, scientifically structured study that evaluates the ability of immediately obtainable young Fresh Frozen Plasma (yFFP) to slow, or prevent the progression of Parkinson’s disease, Multiple Sclerosis and ultimately with further research, other age-related degenerative diseases. Participating registered nurses and our supplier, NuPlasma, all worked diligently to meet our prescriptive requirements, administering extraordinarily high-quality yFFP, which NuPlasma segmented not only by age but also by gender.”
Continuing results from this study will be made available to the public on the website: http://YoungPlasmaStudy.com/
About NuPlasma – NuPlasma is a blood bank operating under FDA, AABB and CLIA’s Good Manufacturing Practice (GMP) regulations that ensure proper collections, processes and shipments of Biologics. Located in San Marcos, Texas, NuPlasma collects young FFP (yFFP) by apheresis without chemical additives or UV irradiation. NuPlasma’s yFFP is immediately frozen, tested and maintained at colder than negative 18ºC to ensure that beneficial proteins remain unaltered and preserved in the native state. The average blood bank performs 12 standard tests, generally releasing each unit three days after collection. In comparison, NuPlasma requires 17 tests and holds each donated unit for 30-days before approved release for use. This procedure allows the donor to make an additional donation ensuring subsequent donations test negative before releasing the initial unit. NuPlasma is dedicated to Making Lives Better® by providing physicians with exceptional quality, selection, and service.
*The use of blood and blood products such as plasma in the United States is restricted only to the issuance of a prescription by a licensed physician.
CONTACT: Lori Freese
EMAIL: [email protected]
For the original news story, please visit https://prdistribution.com/news/young-fresh-frozen-plasma-holds-hope-for-parkinsons-disease-and-multiple-sclerosis-initial-randomized-controlled-study-results-of-young-blood-plasma-treatment-presented-at-2018-a4m-congress.html.
Powered by WPeMatico
Latest posts by Brad Bennett (see all)
- US Capital Global Securities Launches $5 Million Equity Investment in EDP Biotech - January 21, 2019
- Award-winning architect Peter DeMaria is building a better world - January 21, 2019
- Sustainable Growth Fund Helps Win Spot in World Travel & Tourism Council Finals - January 21, 2019